Thinking in Frames

Novo Nordisk's Weight-Loss Revolution

7 min · 22. jan. 2025
episode Novo Nordisk's Weight-Loss Revolution cover

Beskrivelse

Novo Nordisk's success with its GLP-1 receptor agonists, Ozempic and Wegovy, is examined, highlighting the intense competition in the weight-loss drug market. The text explores various factors influencing the company's dominance, including market demand driven by the obesity epidemic, regulatory hurdles and pricing strategies, and internal factors such as strong R&D and strategic alignment. Technological advancements and social trends also played crucial roles. Despite side effects and high costs, the drugs' effectiveness has fueled significant demand.

Kommentarer

0

Vær den første til at kommentere

Tilmeld dig nu og bliv en del af Thinking in Frames-fællesskabet!

Kom i gang

2 måneder kun 19 kr.

Derefter 99 kr. / måned · Opsig når som helst.

  • Podcasts kun på Podimo
  • 20 lydbogstimer pr. måned
  • Gratis podcasts

Alle episoder

8 episoder